Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald Radich

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|March 4, 2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaAnjali S Advani, Shannon McDonough, Steven Coutre, et al.
Medrxiv : the Preprint Server for Health Sciences|June 10, 2024
Evaluation of Acute Myeloid Leukemia Genomes using Genomic Proximity MappingCecilia Cs Yeung, Stephen M Eacker, Olga Sala-Torra, et al.
Leukemia & Lymphoma|November 14, 2014
Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemiaUrsula Rochau, Gaby Sroczynski, Dominik Wolf, et al.
Blood|May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyOliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Haematologica|May 2, 2024
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERNJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Haematologica|January 15, 2026
Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomicsCecilia C S Yeung, Stephen M Eacker, Olga Sala-Torra, et al.
Leukemia & Lymphoma|March 27, 2019
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysisJesus G Berdeja, Michael C Heinrich, Shaker R Dakhil, et al.
Leukemia|April 9, 2020
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized studyJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Journal of Proteome Research|August 21, 2012
Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data setsEric J Foss, Dragan Radulovic, Derek L Stirewalt, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|March 4, 2014
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemiaAnjali S Advani, Shannon McDonough, Steven Coutre, et al.
Medrxiv : the Preprint Server for Health Sciences|June 10, 2024
Evaluation of Acute Myeloid Leukemia Genomes using Genomic Proximity MappingCecilia Cs Yeung, Stephen M Eacker, Olga Sala-Torra, et al.
Leukemia & Lymphoma|November 14, 2014
Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemiaUrsula Rochau, Gaby Sroczynski, Dominik Wolf, et al.
Blood|May 15, 2007
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyOliver Ottmann, Hervé Dombret, Giovanni Martinelli, et al.
American Journal of Hematology|November 6, 2018
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American expertsNicholas J Short, Elias Jabbour, Maher Albitar, et al.
Haematologica|May 2, 2024
Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to 3 months of imatinib therapy: final 5-year results from DASCERNJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Haematologica|January 15, 2026
Evaluation of acute myeloid leukemia using genomic proximity mapping-based next generation cytogenomicsCecilia C S Yeung, Stephen M Eacker, Olga Sala-Torra, et al.
Leukemia & Lymphoma|March 27, 2019
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysisJesus G Berdeja, Michael C Heinrich, Shaker R Dakhil, et al.
Leukemia|April 9, 2020
Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized studyJorge E Cortes, Qian Jiang, Jianxiang Wang, et al.
Journal of Proteome Research|August 21, 2012
Proteomic classification of acute leukemias by alignment-based quantitation of LC-MS/MS data setsEric J Foss, Dragan Radulovic, Derek L Stirewalt, et al.
Pageof 10